vestarВестник аритмологииJournal of Arrhythmology1561-86412658-7327НАО «Инкарт»vestar-101Research ArticleОРИГИНАЛЬНЫЕ СТАТЬИORIGINAL ARTICLEПРЯМЫЕ ОРАЛЬНЫЕ АНТИКОАГУЛЯНТЫ ПРИ ТРОМБОЗЕ ЛЕВОГО ПРЕДСЕРДИЯ У ПАЦИЕНТОВ С ФИБРИЛЛЯЦИЕЙ ПРЕДСЕРДИЙDIRECT ORAL ANTICOAGULANTS IN THE LEFT ATRIAL THROMBOSIS IN PATIENTS WITH ATRIAL FIBRILLATIONРычковА. Ю.RychkovA. Yu.noemail@neicon.ruХорьковаН. Ю.KhorkovaN. Yu.noemail@neicon.ruБелокуроваА. В.BelokurovaA. V.noemail@neicon.ruЯрославскаяЕ. И.YaroslavskayaE. I.noemail@neicon.ruТюменский кардиологический научный центр, Томский национальный исследовательский медицинский центр Российской академии наук; ФГБОУ ВО Тюменский государственный медицинский университет Минздрава РоссииRussian Federation2018170420190916063Copyright © Рычков А.Ю., Хорькова Н.Ю., Белокурова А.В., Ярославская Е.И., 20192019Рычков А.Ю., Хорькова Н.Ю., Белокурова А.В., Ярославская Е.И.Rychkov A.Y., Khorkova N.Y., Belokurova A.V., Yaroslavskaya E.I.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://vestar.elpub.ru/jour/article/view/101

Приводятся клинические наблюдения пациентов с лизисом тромбов в ушке левого предсердия на фоне анти-коагулянтной терапии, обсуждается целесообразность проведения чреспищеводной эхокардиографии перед выполнением кардиоверсии или катетерной изоляции устьев легочных вен у больных с фибрилляцией предсердий.

The clinical observations are given of patients with lysis of the left atrial appendage thrombi at the background of anticoagulant therapy; indications to transesophageal echocardiography before cardioversion or catheter ostial pulmonary vein isolation in patients with atrial fibrillation were discussed.

фибрилляция предсердийушко левого предсердиятромбчреспищеводная эхокардиографияантикоагулянтная терапиякардиоверсиярадиочастотная катетерная аблацияatrial fibrillationleft atrial appendagethrombustransesophageal echocardiographycardioversionradiofrequency catheter ablationReferencesFerner M, Wachtlin D, Konrad T et al. Rationale and design of the RE-LATED AF-AFNET 7 trial: REsolution of Left atrial-Appendage Thrombus--Effects of Dabigatran in patients with Atrial Fibrillation // Clin Res Cardiol. 2016 Jan;105(1):29-36. doi: 10.1007/s00392-015-0883-7.Ferner M, Wachtlin D, Konrad T et al. Rationale and design of the RE-LATED AF-AFNET 7 trial: REsolution of Left atrial-Appendage Thrombus--Effects of Dabigatran in patients with Atrial Fibrillation // Clin Res Cardiol. 2016 Jan;105(1):29-36. doi: 10.1007/s00392-015-0883-7.Kirchhof P., Benussi S., Kotecha D. et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS // European Heart Journal. 2016. 37, 2893-2962. DOI: 10.1093/eurheartj/ehx039Kirchhof P., Benussi S., Kotecha D. et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS // European Heart Journal. 2016. 37, 2893-2962. DOI: 10.1093/eurheartj/ehx039Ревишвили А.Ш., Бойцов С.А., Давтян К.В. и др. Клинические рекомендации по проведению электро-физиологических исследований, катетерной абляции и применению имплантируемых антиаритмических устройств. М. - 2017, 704 с.Ревишвили А.Ш., Бойцов С.А., Давтян К.В. и др. Клинические рекомендации по проведению электро-физиологических исследований, катетерной абляции и применению имплантируемых антиаритмических устройств. М. - 2017, 704 с.Marsico F., Cecere M., Parente A. et al. Effects of novel oral anticoagulants on left atrial and left atrial appendage thrombi: an appraisal // J Thromb Thrombolysis. 2017; 43(2):139-148. doi: 10.1007/s11239-016-1421-9.Marsico F., Cecere M., Parente A. et al. Effects of novel oral anticoagulants on left atrial and left atrial appendage thrombi: an appraisal // J Thromb Thrombolysis. 2017; 43(2):139-148. doi: 10.1007/s11239-016-1421-9.Reers S., Agdirlioglu T., Kellner M. et al. Incidence of left atrial abnormalities under treatment with dabigatran, rivaroxaban, and vitamin K antagonists // Eur J Med Res. 2016; 21;21(1):41.Reers S., Agdirlioglu T., Kellner M. et al. Incidence of left atrial abnormalities under treatment with dabigatran, rivaroxaban, and vitamin K antagonists // Eur J Med Res. 2016; 21;21(1):41.Calkins H., Hindricks G., Cappato R., et al. 2017 HRS/ EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation: Executive summary // J Arrhythm. 2017; 33(5): 369-409. doi: 10.1016/j.joa.2017.08.001.Calkins H., Hindricks G., Cappato R., et al. 2017 HRS/ EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation: Executive summary // J Arrhythm. 2017; 33(5): 369-409. doi: 10.1016/j.joa.2017.08.001.Nagarakanti R., Ezekowitz M.D., Oldgren J. et al. Dabi-gatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion // Circulation. 2011; 18; 123(2): 131-6. doi: 10.1161/CIRCULA-TIONAHA.110.977546.Nagarakanti R., Ezekowitz M.D., Oldgren J. et al. Dabi-gatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion // Circulation. 2011; 18; 123(2): 131-6. doi: 10.1161/CIRCULA-TIONAHA.110.977546.Flaker G., Lopes R.D., Al-Khatib S.M. et al. Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) // J Am Coll Cardiol. 2014; 25; 63(11): 1082-7. doi: 10.1016/j.jacc.2013.09.062.Flaker G., Lopes R.D., Al-Khatib S.M. et al. Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) // J Am Coll Cardiol. 2014; 25; 63(11): 1082-7. doi: 10.1016/j.jacc.2013.09.062.Kawabata M., Goya M., Sasaki T. et al. Left Atrial Appendage Thrombi Formation in Japanese Non-Valvular Atrial Fibrillation Patients During Anticoagulation Therapy - Warfarin vs. Direct Oral Anticoagulants // Circ J. 2017 25; 81(5): 645-651. doi: 10.1253/circj.CJ-16-1089.Kawabata M., Goya M., Sasaki T. et al. Left Atrial Appendage Thrombi Formation in Japanese Non-Valvular Atrial Fibrillation Patients During Anticoagulation Therapy - Warfarin vs. Direct Oral Anticoagulants // Circ J. 2017 25; 81(5): 645-651. doi: 10.1253/circj.CJ-16-1089.Anselmino M., Garberoglio L., Gili S. et al. Left atrial appendage thrombi relate to easily accessible clinical parameters in patients undergoing atrial fibrillation transcatheter ablation: A multicenter study // Int J Cardiol. 2017 15; 241: 218-222. doi: 10.1016/j.ijcard.2017.04.014.Anselmino M., Garberoglio L., Gili S. et al. Left atrial appendage thrombi relate to easily accessible clinical parameters in patients undergoing atrial fibrillation transcatheter ablation: A multicenter study // Int J Cardiol. 2017 15; 241: 218-222. doi: 10.1016/j.ijcard.2017.04.014.Gunawardene M.A., Dickow J., Schaeffer B.N. et al. Risk stratification of patients with left atrial appendage thrombus prior to catheter ablation of atrial fibrillation: An approach towards an individualized use of transesophageal echocardiography // J Cardiovasc Electrophysiol. 2017; 28(10): 1127-1136. doi: 10.1111/jce.13279.Gunawardene M.A., Dickow J., Schaeffer B.N. et al. Risk stratification of patients with left atrial appendage thrombus prior to catheter ablation of atrial fibrillation: An approach towards an individualized use of transesophageal echocardiography // J Cardiovasc Electrophysiol. 2017; 28(10): 1127-1136. doi: 10.1111/jce.13279.Lip G.Y., Hammerstingl C., Marin F. et al. Rationale and design of a study exploring the efficacy of once-daily oral rivaroxaban (X-TRA) on the outcome of left atrial/left atrial appendage thrombus in nonvalvular atrial fibrillation or atrial flutter and a retrospective observational registry providing baseline data (CLOT-AF) // Am Heart J. 2015; 169(4): 464-71.e2. doi: 10.1016/ j.ahj.2014.12.020.Lip G.Y., Hammerstingl C., Marin F. et al. Rationale and design of a study exploring the efficacy of once-daily oral rivaroxaban (X-TRA) on the outcome of left atrial/left atrial appendage thrombus in nonvalvular atrial fibrillation or atrial flutter and a retrospective observational registry providing baseline data (CLOT-AF) // Am Heart J. 2015; 169(4): 464-71.e2. doi: 10.1016/ j.ahj.2014.12.020.Ammollo C.T., Semeraro F., Incampo F. et al. Dabiga-tran enhances clot susceptibility to fibrinolysis by mechanisms dependent on and independent of thrombin-activat-able fibrinolysis inhibitor // J Thromb Haemost. 2010; 8(4): 790-8. doi: 10.1111/j.1538-7836.2010.03739.x.Ammollo C.T., Semeraro F., Incampo F. et al. Dabiga-tran enhances clot susceptibility to fibrinolysis by mechanisms dependent on and independent of thrombin-activat-able fibrinolysis inhibitor // J Thromb Haemost. 2010; 8(4): 790-8. doi: 10.1111/j.1538-7836.2010.03739.x.Lip G.Y, Hammerstingl C., Marin F. et al. Left atrial thrombus resolution in atrial fibrillation or flutter: Results of a prospective study with rivaroxaban (X-TRA) and a retrospective observational registry providing baseline data (CLOT-AF) // Am Heart J. 2016; 178: 126-34. doi: 10.1016/j.ahj.2016.05.007.Lip G.Y, Hammerstingl C., Marin F. et al. Left atrial thrombus resolution in atrial fibrillation or flutter: Results of a prospective study with rivaroxaban (X-TRA) and a retrospective observational registry providing baseline data (CLOT-AF) // Am Heart J. 2016; 178: 126-34. doi: 10.1016/j.ahj.2016.05.007.Ezekowitz M.D., Pollack C.V, Sanders P. et al. Apixaban compared with parenteral heparin and/or vitamin K antagonist in patients with nonvalvular atrial fibrillation undergoing cardioversion: Rationale and design of the EMANATE trial // Am Heart J. 2016; 179: 59-68. doi: 10.1016/j.ahj.2016.06.008.Ezekowitz M.D., Pollack C.V, Sanders P. et al. Apixaban compared with parenteral heparin and/or vitamin K antagonist in patients with nonvalvular atrial fibrillation undergoing cardioversion: Rationale and design of the EMANATE trial // Am Heart J. 2016; 179: 59-68. doi: 10.1016/j.ahj.2016.06.008.Kawano H., Kohno Y., Izumida S. et al. Rivaroxaban therapy resulting in the resolution of right atrial thrombosis resistant to ordinary control with warfarin in a patient with atrial fibrillation // Intern Med. 2015; 54(6): 601-4. doi: 10.2169/internalmedicine.54.3003.Kawano H., Kohno Y., Izumida S. et al. Rivaroxaban therapy resulting in the resolution of right atrial thrombosis resistant to ordinary control with warfarin in a patient with atrial fibrillation // Intern Med. 2015; 54(6): 601-4. doi: 10.2169/internalmedicine.54.3003.Miwa Y, Minamishima T., Sato T. et al. Resolution of a warfarin and dabigatran-resistant left atrial appendage thrombus with apixaban // J Arrhythm. 2016; 32(3): 233-5. doi: 10.1016/j.joa.2016.01.009.Miwa Y, Minamishima T., Sato T. et al. Resolution of a warfarin and dabigatran-resistant left atrial appendage thrombus with apixaban // J Arrhythm. 2016; 32(3): 233-5. doi: 10.1016/j.joa.2016.01.009.Szegedi N., Geller L., Tahin T. et al. Successful direct thrombin inhibitor treatment of a left atrial appendage thrombus developed under rivaroxaban therapy // Orv Hetil. 2016 24; 157(4): 154-6. doi: 10.1556/650.2016.30350.Szegedi N., Geller L., Tahin T. et al. Successful direct thrombin inhibitor treatment of a left atrial appendage thrombus developed under rivaroxaban therapy // Orv Hetil. 2016 24; 157(4): 154-6. doi: 10.1556/650.2016.30350.Koyama T., Otsuka Y., Kawahara M. et al. A left atrial appendage thrombus that developed during prophylactic low-dose dabigatran treatment resolved after switching to apixaban // Clin Case Rep. 2017 31; 5(5): 711-713. doi: 10.1002/ccr3.933.Koyama T., Otsuka Y., Kawahara M. et al. A left atrial appendage thrombus that developed during prophylactic low-dose dabigatran treatment resolved after switching to apixaban // Clin Case Rep. 2017 31; 5(5): 711-713. doi: 10.1002/ccr3.933.Lau Y.C., Xiong Q., Shantsila E. et al. Effects of nonvitamin K antagonist oral anticoagulants on fibrin clot and whole blood clot formation, integrity and thrombolysis in patients with atrial fibrillation // J Thromb Thrombolysis. 2016; 42(4): 535-44. doi: 10.1007/s11239-016-1399-3.Lau Y.C., Xiong Q., Shantsila E. et al. Effects of nonvitamin K antagonist oral anticoagulants on fibrin clot and whole blood clot formation, integrity and thrombolysis in patients with atrial fibrillation // J Thromb Thrombolysis. 2016; 42(4): 535-44. doi: 10.1007/s11239-016-1399-3.

The authors declare that there are no conflicts of interest present.